# The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer

> **NCT01268163** · PHASE1 · COMPLETED · sponsor: **Hospira, now a wholly owned subsidiary of Pfizer** · enrollment: 32 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** European Taxotere®
- **DRUG:** American Taxotere®
- **DRUG:** Hospira Docetaxel Injection

## Key facts

- **NCT ID:** NCT01268163
- **Lead sponsor:** Hospira, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01268163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01268163, "The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01268163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*